Crossmark

Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)

Crossref DOI link: https://doi.org/10.1136/jitc-2020-001504

Published Online: 2021-03-25

Published Print: 2021-03

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Ricciuti, Biagio https://orcid.org/0000-0002-0651-2678
Jones, Greg

Severgnini, Mariano

Alessi, Joao V https://orcid.org/0000-0002-8072-5946
Recondo, Gonzalo

Lawrence, Marissa

Forshew, Tim

Lydon, Christine

Nishino, Mizuki

Cheng, Michael

Awad, Mark
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct04166487 at ClinicalTrials.gov

Documents that mention this clinical trial

Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy
https://doi.org/10.1136/jitc-2022-005924

Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)
https://doi.org/10.1136/jitc-2020-001504
License Information

License valid from 2021-03-24